Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease

Journal of Neuroscience

Volumn 22, Issue 5, 2002, Pages 1592-1599

  Ferrante, Robert J ^a,b   Andreassen, Ole A ^c   Dedeoglu, Alpaslan ^a,b   Ferrante, Kimberly L ^e   Jenkins, Bruce G ^d   Hersch, Steven M ^d   Beal, M Flint ^e,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Neurochemistry Laboratory   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Coenzyme Q10; Excitotoxicity; Huntington's disease; Mitochondria; Remacemide; Transgenic

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; REMACEMIDE; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN VENTRICLE; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; FEMALE; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE;

EID: 0036523110     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-05-01592.2002     Document Type: Article

References (47)

1. Abe K, Fujimura H, Nishikawa Y, Yorifuki S, Mezaki T, Hirono N, Nishitani N, Kameyama M (1991) Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 83:356-359.
2. Bannan PE, Graham DI, Lees KR, McCulloch J (1994) Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res 664:271-275.
3. Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:294-300.
4. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:4181-4192.
5. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993a) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192.
6. Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT (1993b) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 61:1147-1150.
7. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 36:882-888.
8. Beyer RE (1992) An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 70:390-403.
9. Black MA, Tremblay R, Mealing G, Ray R, Durkin JP, Whitfield JF, Blosser J, Morley P (1995) N-methyl-D-aspartate- or glutamate-mediated toxicity in cultured rat cortical neurons is antagonized by FPL 15896AR. J Neurochem 65:2170-2177.
10. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105-7109.
11. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MMK, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann Neurol 41:646-653.
12. Chariot P, Brugieres P, Eliezer-Vanerot MC, Geny C, Binaghi M, Cesaro P (1999) Choreic movements and MRI abnormalities in the subthalamic nuclei reversible after administration of coenzyme Q10 and multiple vitamins in a patient with bilateral optic neuropathy. Mov Disord 14:855-859.
13. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of huntington disease. Nat Med 6:797-801.
14. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiari L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-548.
15. Dyker AG, Lees KR (1999) Remacemide hydrochloride: A double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke 30:1796-1801.
16. Ferrante RJ, Kowall NW, Cipolloni PB, Beal MF (1993) Excitotoxin lesions in primates as a model of Huntington's disease: Histopathologic and neurochemical characterization. Exp Neurol 119:46-71.
17. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20:4389-4397.
18. Franklin KBJ, Paxinos G (1997) The Mouse Brain in Stereotaxic Coordinates. New York: Academic.
19. Greene JG, Porter RH, Eller RV, Greenamyre JT (1993) Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 61:1151-1154.
20. Greene JG, Porter RH, Greenamyre JT (1996) ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: Neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp Neurol 137:66-72.
21. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385-389.
22. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 96:8727-8732.
23. 10 and remacemide in Huntington's disease. Neurology 57:401-404.
24. 10 and idebenone. J Neurol Sci 90:263-271.
25. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43:2689-2695.
26. Kieburtz K (1999) Antiglutamate therapies in Huntington's disease. J Neural Transm Suppl 55:97-102.
27. Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre JT, Dunn C, Shoulson I (1996) A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 11:273-277.
28. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 41:160-165.
29. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ (1999) Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46:842-849.
30. Lass A, Forster MJ, Sohal RS (1999) Effects of coenzyme Q10 and α-tocopherol administration on their tissue levels in the mouse: Elevation of mitochondrial α-tocopherol by coenzyme Q10. Free Radic Biol Med 26:1375-1382.
31. Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 3:157-163.
32. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 48:72-76.
33. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, Olson JM (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9:1259-1271.
34. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
35. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95:8892-8897.
36. McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263:517-519.
37. 31P NMR study. Neurology 39:399-403.
38. Noack H, Kube U, Augustin W (1994) Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic Res 20:375-386.
39. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-267.
40. 10 on biochemical and morphological changes in experimental ischemia in the rat brain. Brain Res Bull 53:399-407.
41. Porter RH, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential. J Neurochem 64:614-623.
42. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler Jr JF, Greenamyre JT, Snyder SH, Ross CA (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat lengthdependent mitochondrial depolarization. Nat Med 5:1194-1198.
43. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397-407.
44. Schulz JB, Matthews RT, Henshaw DR, Beal MF (1996) Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience 71:1043-1048.
45. Schwarcz R, Coyle JT (1976) Adenylate cyclase activity in chick retina. Gen Pharmacol 7:349-354.
46. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
47. Zeron MM, Wellington CL, Krebs C, Leavin BR, Baimbridge K, Hayden MR, Raymond LA (2001) Enhanced sensitivity to N-methyl-Daspartate receptor-mediated excitotoxicity in a transgenic mouse model of Huntington's disease. Soc Neurosci 27:1150.